Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company focused on innovative cancer treatments, has announced the issuance of 333 restricted stock units (RSUs) to a newly-hired employee. The grant, effective as of July 31, 2025, is part of the company's 2022 Inducement Stock Incentive Plan. These RSUs will vest over three years, with equal portions vesting on each anniversary of the grant date, contingent upon continued employment. Additionally, the RSUs will fully vest should the employee be terminated without cause, or resign for good reason, within a year following a change in control event. This move is in accordance with Nasdaq Listing Rule 5635(c)(4).
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。